Endobronchial lipoma

Summary

Endobronchial lipoma (MONDO:0000961) is a disease. A subtype of respiratory system benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endobronchial lipoma
Mondo ID	MONDO:0000961
DOID	DOID:10183
NCIT	C5063
UMLS	C0852937
MedGen	208874
Anatomy (UBERON)	UBERON:0007196
Is cancer (heuristic)	no

Also known as: endobronchial lipoma

Disease family

This is a subtype of respiratory system benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › respiratory system benign neoplasm › endobronchial lipoma

Related subtypes (14): benign laryngeal neoplasm, lung benign neoplasm, paranasal sinus Schneiderian papilloma, benign neoplasm of pleura, benign neoplasm of hypopharynx, benign neoplasm of nasal cavity, benign neoplasm of sphenoidal sinus, benign neoplasm of nasopharynx, benign neoplasm of oropharynx, benign neoplasm of frontal sinus, benign neoplasm of maxillary sinus, benign neoplasm of tonsil, benign neoplasm of ethmoidal sinus, benign neoplasm of trachea

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.